Abstract:Neuraminidase (NA) is a pivotal surface enzyme and a key therapeutic target in combating the influenza A virus. Its evolution can lead to potential zoonotic transmission, seasonal epidemics, and the emergence of drug-resistant mutants. To gain comprehensive insights into the mutational effects and drug resistance profiles of NA, we employed a high-throughput profiling system to quantify the replication capacity of NA mutants at the single-nucleotide level in mouse lung tissues. The fitness of NA mutants is generally correlated with natural mutation occurrence and is constrained by both the requirement to maintain protein stability and NA function. Leveraging this system, we profiled the drug resistance to the three most commonly used neuraminidase inhibitors (NAIs): zanamivir, oseltamivir, and peramivir. In addition to identifying previously reported drug resistance mutations, we validated novel mutants. Notably, we identified an allosteric mutation that confers resistance to all three drugs, which may affect drug binding by interfering with the tetramerization of NA. Moreover, the fitness cost associated with drug-resistant mutations may limit their widespread dissemination. In summary, we provided a parallel characterization of NA's fitness and drug resistance landscape in an context, which may guide the rational selection of antiviral drugs for optimal therapeutic efficacy and second-generation NAI development. IMPORTANCE NA is a crucial surface antigen and drug target of influenza A virus. A comprehensive understanding of NA's mutational effect and drug resistance profiles is essential for comprehending the evolutionary constraints and making informed choices regarding drug selection to combat resistance in clinical settings. In the current study, we established an efficient deep mutational screening system in mouse lung tissues and systematically evaluated the fitness effect and drug resistance to three neuraminidase inhibitors of NA single-nucleotide mutations. The fitness of NA mutants is generally correlated with a natural mutation in the database. The fitness of NA mutants is influenced by biophysical factors such as protein stability, complex formation, and the immune response triggered by viral infection. In addition to confirming previously reported drug-resistant mutations, novel mutations were identified. Interestingly, we identified an allosteric drug-resistance mutation that is not located within the drug-binding pocket but potentially affects drug binding by interfering with NA tetramerization. The dual assessments performed in this study provide a more accurate assessment of the evolutionary potential of drug-resistant mutations and offer guidance for the rational selection of antiviral drugs.

Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico

Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico.

Develop integration modeling approach for discovery neuraminidase inhibitors in silico based on pharmacophore and CoMSIA models

Design, Synthesis and Biological Evaluation of "Multi-Site"-binding Influenza Virus Neuraminidase Inhibitors.

Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH2-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors

Design, synthesis, bioactivity, and DFT calculation of 2-thiazolyl-hydrazone derivatives as influenza neuraminidase inhibitors

Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo .

Pharmacophore-based virtual screening, molecular docking and molecular dynamics studies for the discovery of novel neuraminidase inhibitors

Design, synthesis and biological evaluation of sulfamethazine derivatives as potent neuraminidase inhibitors

Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.

3D-QSAR Pharmacophore-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulation Toward Identifying Lead Compounds for NS2B-NS3 Protease Inhibitors.

Structure-activity relationships of saponin derivatives: a series of entry inhibitors for highly pathogenic H5N1 influenza virus.

Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors via Targeting 150-Cavity

Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors

Identification of C5-NH2 Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability

A Novel N-heterocycles Substituted Oseltamivir Derivatives As Potent Inhibitors of Influenza Virus Neuraminidase: Discovery, Synthesis and Biological Evaluation

Design, synthesis, and biological activity of a novel series of 2-ureidonicotinamide derivatives against influenza A virus

Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity

In Vitro Antiviral Effects and 3d Qsar Study of Resveratrol Derivatives As Potent Inhibitors of Influenza H1n1 Neuraminidase

Discovery and Characterization of a Novel Peptide Inhibitor Against Influenza Neuraminidase

Discovering Neuraminidase Inhibitors via Computational and Experimental Studies